Quinine in Covid-19 Repurposing for Impact | OMICS International | Abstract
ISSN: 2332-0877

Journal of Infectious Diseases & Therapy
Open Access

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Quinine in Covid-19 Repurposing for Impact

*Corresponding Author:

Copyright: © 0  . This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

To read the full article Peer-reviewed Article PDF image


Quinine repurposing for use in moderate to severe COVID-19 is empirically utilized on a physician-patient basis, adduced from the
(LWI) study protocols for COVID-19 Response, a monologue of protocols which had been hypothesis-tested, and debated for 6 weeks
prior. The three (3) sets of study protocol S6 were compiled with a goal to arriving at a practical and affordable solution to the pandemic.
Having undergone debates and hypothesis testing among physicians, researchers and virologists, they are still undergoing random
physician-patient trials at the discretion of prescribers and researchers.
They are study protocols designed to ‘evolve’ as a solution to COVID-19 response. Having tested for the repurposing of Chloroquine
and Hydroxychloroquine. 1 in moderate to severe COVID-19 with little success, their use is now assigned to prophylaxis, for a future study.
The LWI study protocols strongly suggest the use of Quinine for COVID-19 treatment in moderate to advanced disease, recommending
intravenous infusion of Quinine for critical care in COVID-19.
In conclusion, although the sample size of the preliminary study was small, Quinine is impactful with positive outcomes for severe or
advanced COVID-19 especially after the cytokine storm, with 5-7 days total recovery after the onset of the cytokine storm. Our preliminary
study also found that CQ/HCQ may be very useful for prophylaxis and pre-emptive treatment in COVID-19. In furtherance to this study,
we are recommending strongly that a full study should be commissioned to establish


Recommended Conferences
Share This Page